FibroBiologics (NASDAQ:FBLG) Earns “Buy” Rating from HC Wainwright

FibroBiologics (NASDAQ:FBLG)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $12.00 target price on the stock.

Other equities analysts also recently issued research reports about the company. D. Boral Capital restated a “buy” rating and issued a $16.00 price objective on shares of FibroBiologics in a report on Thursday, February 27th. Rodman & Renshaw initiated coverage on shares of FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 price target on the stock. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Stock Down 5.3 %

Shares of FBLG stock opened at $0.90 on Tuesday. FibroBiologics has a fifty-two week low of $0.90 and a fifty-two week high of $13.59. The stock’s 50-day moving average is $1.30 and its two-hundred day moving average is $2.16.

Hedge Funds Weigh In On FibroBiologics

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its position in FibroBiologics by 90.0% during the 3rd quarter. Geode Capital Management LLC now owns 599,760 shares of the company’s stock worth $1,854,000 after acquiring an additional 284,047 shares during the last quarter. State Street Corp increased its stake in shares of FibroBiologics by 26.5% in the third quarter. State Street Corp now owns 475,837 shares of the company’s stock worth $1,470,000 after purchasing an additional 99,789 shares during the period. Jane Street Group LLC lifted its position in shares of FibroBiologics by 415.3% during the 4th quarter. Jane Street Group LLC now owns 61,074 shares of the company’s stock worth $122,000 after purchasing an additional 49,222 shares during the last quarter. O Shaughnessy Asset Management LLC bought a new stake in FibroBiologics during the 4th quarter valued at approximately $81,000. Finally, Barclays PLC grew its holdings in FibroBiologics by 363.2% in the 3rd quarter. Barclays PLC now owns 39,958 shares of the company’s stock valued at $123,000 after buying an additional 31,331 shares during the last quarter.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.